Are you Dr. Piperdi?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 57 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
55 Lake Ave N
Department Of Hematology/Oncology
Worcester, MA 01655Phone+1 508-856-3933
Summary
- Dr. Bilal Piperdi, MD is an oncologist in Worcester, Massachusetts. He is currently licensed to practice medicine in Massachusetts and New York. He is an Assistant Professor at University Massachusetts Medical School.
Education & Training
Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Fellowship, Hematology and Medical Oncology, 2001 - 2004
SUNY Upstate Medical UniversityResidency, Internal Medicine, 1998 - 2001
Hacettepe University FOMClass of 1997
Certifications & Licensure
NY State Medical License 2011 - 2026
MA State Medical License 2004 - 2012
Clinical Trials
- Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Start of enrollment: 2005 Nov 01
- Pemetrexed Disodium With or Without Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV or Recurrent Non-Small Cell Lung Cancer Start of enrollment: 2006 Apr 01
- A Pilot Study to Evaluate the Efficacy and Safety of Neoadjuvant Chemoradiotherapy With Capecitabine, . . . Start of enrollment: 2010 May 01
- Join now to see all
Publications & Presentations
PubMed
- 20 citationsAssociations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC.Marina C Garassino, Shirish Gadgeel, Silvia Novello, Balazs Halmos, Enriqueta Felip
JTO Clinical and Research Reports. 2023-01-01 - 3 citationsIndirect comparison of pembrolizumab monotherapy versus nivolumab + ipilimumab in first-line metastatic lung cancer.Balazs Halmos, Thomas Burke, Chrysostomos Kalyvas, Ralph Insinga, Kristel Vandormael
Immunotherapy. 2022-04-01 - 138 citationsFive Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1-Positive Advanced NSCLC.Roy S. Herbst, Edward B. Garon, Dong Wan Kim, Byoung Chul Cho, Radj Gervais
Journal of Thoracic Oncology. 2021-10-01
Press Mentions
An Expert Take on Lung CancerNovember 26th, 2019
Professional Memberships
- Member
